Developing the EAVE III platform for future health crises

Colin R Simpson; Chris Robertson; Jim McMenamin; Lewis D Ritchie; Aziz Sheikh

doi:10.1016/S1473-3099(23)00626-6

Developing the EAVE III platform for future health crises

Colin R Simpson^* (Corresponding Author), Chris Robertson, Jim McMenamin, Lewis D Ritchie, Aziz Sheikh

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The Scottish Early Estimation of Pandemic Influenza Antiviral and Vaccine Effectiveness (EAVE) platform was established in 2012 through funding from the National Institute for Health Research, alongside a portfolio of nine pandemic preparedness and responsiveness projects consequent to the 2009 influenza A/H1N1 pandemic.1, 2, 3 In response to the emergence of COVID-19, funding was made available by a range of UK funders to support studies that could rapidly respond to this new pandemic. No precedent existed for a whole-country population platform; therefore, funding from the UK Research and Innovation–Medical Research Council and the Scottish Government was used to bring the EAVE platform out of hibernation and create the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) platform, the first national, real-time, multidimensional, surveillance platform in the world, with data from all residents in Scotland.

Original language	English
Pages (from-to)	1223-1225
Number of pages	3
Journal	Lancet Infectious Diseases
Volume	23
Issue number	11
Early online date	25 Oct 2023
DOIs	https://doi.org/10.1016/S1473-3099(23)00626-6
Publication status	Published - Nov 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1473-3099(23)00626-6Licence: Unspecified

Cite this

@article{fec0e1d080cd49d1a8330424480c7dd3,

title = "Developing the EAVE III platform for future health crises",

abstract = "The Scottish Early Estimation of Pandemic Influenza Antiviral and Vaccine Effectiveness (EAVE) platform was established in 2012 through funding from the National Institute for Health Research, alongside a portfolio of nine pandemic preparedness and responsiveness projects consequent to the 2009 influenza A/H1N1 pandemic.1, 2, 3 In response to the emergence of COVID-19, funding was made available by a range of UK funders to support studies that could rapidly respond to this new pandemic. No precedent existed for a whole-country population platform; therefore, funding from the UK Research and Innovation–Medical Research Council and the Scottish Government was used to bring the EAVE platform out of hibernation and create the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) platform, the first national, real-time, multidimensional, surveillance platform in the world, with data from all residents in Scotland.",

author = "Simpson, {Colin R} and Chris Robertson and Jim McMenamin and Ritchie, {Lewis D} and Aziz Sheikh",

year = "2023",

month = nov,

doi = "10.1016/S1473-3099(23)00626-6",

language = "English",

volume = "23",

pages = "1223--1225",

journal = "Lancet Infectious Diseases",

issn = "1473-3099",

publisher = "ELSEVIER APPL SCI PUBL LTD",

number = "11",

}

TY - JOUR

T1 - Developing the EAVE III platform for future health crises

AU - Simpson, Colin R

AU - Robertson, Chris

AU - McMenamin, Jim

AU - Ritchie, Lewis D

AU - Sheikh, Aziz

PY - 2023/11

Y1 - 2023/11

N2 - The Scottish Early Estimation of Pandemic Influenza Antiviral and Vaccine Effectiveness (EAVE) platform was established in 2012 through funding from the National Institute for Health Research, alongside a portfolio of nine pandemic preparedness and responsiveness projects consequent to the 2009 influenza A/H1N1 pandemic.1, 2, 3 In response to the emergence of COVID-19, funding was made available by a range of UK funders to support studies that could rapidly respond to this new pandemic. No precedent existed for a whole-country population platform; therefore, funding from the UK Research and Innovation–Medical Research Council and the Scottish Government was used to bring the EAVE platform out of hibernation and create the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) platform, the first national, real-time, multidimensional, surveillance platform in the world, with data from all residents in Scotland.

AB - The Scottish Early Estimation of Pandemic Influenza Antiviral and Vaccine Effectiveness (EAVE) platform was established in 2012 through funding from the National Institute for Health Research, alongside a portfolio of nine pandemic preparedness and responsiveness projects consequent to the 2009 influenza A/H1N1 pandemic.1, 2, 3 In response to the emergence of COVID-19, funding was made available by a range of UK funders to support studies that could rapidly respond to this new pandemic. No precedent existed for a whole-country population platform; therefore, funding from the UK Research and Innovation–Medical Research Council and the Scottish Government was used to bring the EAVE platform out of hibernation and create the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) platform, the first national, real-time, multidimensional, surveillance platform in the world, with data from all residents in Scotland.

U2 - 10.1016/S1473-3099(23)00626-6

DO - 10.1016/S1473-3099(23)00626-6

M3 - Comment/debate

C2 - 37839426

SN - 1473-3099

VL - 23

SP - 1223

EP - 1225

JO - Lancet Infectious Diseases

JF - Lancet Infectious Diseases

IS - 11

ER -

Developing the EAVE III platform for future health crises

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this